Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine

Published: Wednesday, February 27, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Adds former LabCorp leader Thomas Mac Mahon to board of directors, expects further growth in 2013.

With a range of products and services driving the development of personalized medicine, Aushon Biosystems has appointed Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors. The expansion of its board builds on Aushon’s recent momentum as it is poised for significant growth in 2013.

Aushon provides a suite of multiplex immunoassay products and services for the discovery and development of the biomarkers necessary to enable personalized medicine innovation. Aushon’s multiplex approach involves simultaneously measuring and comparing multiple proteins – which eliminates the cost and time obstacles that have traditionally been associated with personalized medicine development with the singleplex ELISA platform.

“Multiplex technology allows us to cast a wider net across a diverse array of biologies known to play a role in the development of cancer and determine the response of pharmacological agents on them,” said Dr. Andrew Nixon, associate professor of medicine and director of the Phase I Biomarker Laboratory at Duke University. “Using this research approach, we’re better able to allocate our limited resources – both patient sample and money – for optimal success.”

Life sciences and diagnostics industry veteran Mac Mahon took notice of Aushon’s multiplex approach as critical to the future of personalized medicine.

“The current gold-standard approach to protein analysis comes with unnecessary cost and time barriers that prevent personalized medicine from becoming a reality for all,” said Mac Mahon. “I’m excited to continue my work advancing diagnostics and personalized medicine advancement with Aushon – which has created the approach that breaks down the current barriers – and will drive the future of personalized medicine.”

Mac Mahon served as chairman of LabCorp from 1996 to 2009 and as CEO and president from 1997 to 2006. Previously, he held the roles of senior vice president of Hoffmann-La Roche Inc., president of Roche Diagnostics Group, and chairman of PharMerica Corporation. Mac Mahon has also been presiding director of Aristotle Holding, Inc. and Express Scripts Holding Company since May 2008 and also serves as a director of SynapDx Corporation.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer
Former SeraCare CEO and Millipore executive to guide strategic direction of life sciences services and technology company.
Tuesday, April 16, 2013
Aushon BioSystems and Peking University Cancer Hospital to Collaborate
Aushon BioSystems, Inc. announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital (“PUCH”), Beijing, China. The primary goal for the collaboration is to develop predictive diagnostic markers for liver metastases of colorectal cancer.
Friday, February 11, 2011
Aushon and PUCH Collaboration to Focus on Predictive Diagnostic Biomarkers for Liver Metastases of Colorectal Cancer
Company’s collaborate to develop markers for liver metastases utilizing Aushon’s protein biomarker detection technologies, and stratification biomarkers for radio-chemotherapy patients.
Wednesday, February 09, 2011
Aushon Appoint New Chief Scientific Officer
Aushon, a provider of advanced microarray products and laboratory services for biomarker discovery, have announced that Sven Beushausen, Ph.D., has been appointed to the position of Chief Scientific Officer.
Wednesday, November 24, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Kitchen Utensils Can Spread Bacteria Between Foods
In a recent study researchers found that produce that contained bacteria would contaminate other produce items through the continued use of knives or graters—the bacteria would latch on to the utensils commonly found in consumers' homes and spread to the next item.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Safer, Faster Way To Remove Pollutants From Water
Using nanoparticles filled with enzymes proves more effective than current methods.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Novel Tumor Treatment
In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos has been published.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
New Analysis Technique for Chiral Activity in Molecules
Professor Hyunwoo Kim of the Chemistry Department and his research team have developed a technique that can easily analyze the optical activity of charged compounds by using nuclear magnetic resonance (NMR) spectroscopy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos